Search Results

<< Back to podcast list Strategic Partner(s) Brian Shoichet About Dr. Brian Shoichet BSc in Chemistry from MIT, Ph.D. with Tack Kuntz at UCSF; Postdoc with Brian Matthews crystallography; started my independent lab at Northwestern University Medical School (1996) was recruited back

. << Back to podcast list Strategic Partner(s) Hacking GPCRs: Tools, Tech & Drug Discovery with Tom Sakmar In Ilana’s words, it’s a powerful way to “go from many back to one.”

<< Back to podcast list Strategic Partner(s) Dr. Demet Araç About Dr. He explained that initially, the field lacked adequate tools, and his lab had to develop new techniques Demet shared his belief that he was driven by a biological need to tackle more challenging tasks.

. << Back to podcast list Strategic Partner(s) Aaron Sato: Synthetic Antibody Libraries for the Hardest Phage display's ~10¹⁰ variant ceiling can be broken by stacking libraries. Aaron has a proven track record as a biologics leader as he led teams to discover and develop novel first-in-class Twist Bioscience’s proprietary technology to manufacture DNA at a scale, the team saw an opportunity to tackle

. << Back to podcast list Strategic Partner(s) Yamina Berchiche: Beyond the Lab — From Chemokine Receptors newsletters, summits, and working spaces designed to give the field connective tissue it has historically lacked The lab had no equipment, only stacks of bills on every bench — and a research program on chemokines were generated using AI for readability. 00:00 Introduction 02:25 The closet studio and what's in the talk I gave a talk on October 12th at the 3rd ERNEST meeting about the Dr.GPCR Ecosystem .

<< Back to podcast list Strategic Partner(s) Dr. Katarina Nemec About Dr. to combine experimental approaches with data-driven discovery and adopt data science methodology to tackle

. < Back to Webinars 📅 Thursday, June 25, 2026 at 3:00:00 PM UTC 🤝 Webinar in collaboration with: GeneTex A reagent gap that holds back the biology GPCR activity is targeted by one-third of all FDA-approved GeneTex is tackling that problem with a high-throughput recombinant antibody platform paired with enhanced

<< Back to podcast list Strategic Partner(s) Dr. Bianca Plouffe About Dr. Bianca Plouffe Dr. of Bouvier’s team, Bianca used Bioluminescence Resonance Energy Transfer (BRET)-based technology to tackle

<< Back to podcast list Strategic Partner(s) Dr. Simone Prömel & Dr. Ines Liebscher About Dr. With the little knowledge on these receptors available, there were multiple questions to tackle.

<< Back to podcast list Strategic Partner(s) Dr. Claudia Stäubert About Dr. Yamina expressed interest in learning more about this topic as she realized her lack of knowledge on topic, with Claudia concluding that diseases might first affect the metabolites and not necessarily lack

<< Back to podcast list Strategic Partner(s) Dr. Michael Feigin About Dr. Michael Feigin "Dr. Mike also spoke about his initial struggles during his Ph.D., such as a difficult model system and a lack Mike expressed his initial reluctance due to a lack of confidence and fear of not being ready. Mike reflected on his early years as a postdoc, admitting that he lacked focus and didn't see the direct

. << Back to podcast list Strategic Partner(s) From Curiosity to Breakthrough: Ajay Yekkirala on GPCR Originally on track to pursue an MD/PhD, a rejection letter pivoted him into a PhD program at the University Driven by the opioid crisis and the lack of non-addictive pain treatments, Ajay co-founded Blue Therapeutics

. << Back to podcast list Strategic Partner(s) Xylazine, Fentanyl, and the Fight for Breath with Catherine different mechanisms—work that blends receptor pharmacology, preclinical models, and public health data to tackle

. << Back to podcast list Strategic Partner(s) Charlotte Crauwels: Designing Hybrid GPCRs with Computational families in pharmacology and drug discovery, yet many receptors remain poorly characterized or “orphan,” lacking Looking back, my path to this work was not very linear. Yamina Berchiche: Looking back at your PhD trajectory, what originally drew you to computational research Yamina Berchiche: Let’s talk about your PhD project. What was the core idea behind your research?

. << Back to podcast list Strategic Partner(s) Custom Molecules, Fluorescent Probes: When Chemists Think expand its visibility and impact—offering its expertise, tools, and real-world insight to researchers tackling

<< Back to podcast list Strategic Partner(s) A Brief History of allosteric modulation with Dr. underscored the potential of allosteric modulators as drugs, despite challenges in the past due to a lack

. << Back to podcast list Strategic Partner(s) Smells Like GPCR Spirit: Cracking Olfactory Codes with thing.” – Alessandro Nicoli He reflected on learning to delegate—how hard it was initially to hand over tasks—but Despite their relevance, they remain understudied due to the limited knowledge of their ligands and the lack

<< Back to podcast list Strategic Partner(s) Dr. Aurélien Rizk About Dr. Aurélien Rizk "Dr. He also talked about his past experiences in mathematics, physics, and computer sciences, and his involvement They highlighted that while there was a time when biology lagged due to the lack of appropriate tools

. << Back to podcast list Strategic Partner(s) Jacob Lee and Jin Cho: Rebuilding the Software Layer Under They talk about the slow architecture of drug discovery, the compounding cost of irreproducibility, and different majors, different career paths, and a late-night message asking whether lab software could be hacked

<< Back to podcast list Strategic Partner(s) Dr. John Janetzko About Dr. The conversation emphasized the importance of diverse backgrounds and skill sets in tackling complex

. << Back to podcast list Strategic Partner(s) Joseph Kim: Structural Biology and Drug Discovery at GPCRs The lack of potent small-molecule ligands continues to hinder research into these receptors. 6. I listened to one of his talks at a Gordon Conference and he was phenomenal. I remember distinctly sitting back one day and thinking: “Ah crud… I’m going to have to study GPCRs, I just looked it up while we were talking.

. << Back to podcast list Strategic Partner(s) EARNEST Panel: Can AI Accelerate GPCR Drug Discovery? which account for a large fraction of the receptor class — have been systematically sidestepped for lack

. << Back to podcast list Strategic Partner(s) Dr. TRV-130 was denied FDA approval for lack of clear safety advantage.

Terry Kenakin < Back Workshop Summary Join Dr. avoiding unwanted side effects. 🗣️ Interactive Q&A : The discussion wraps up with an insightful Q&A, tackling The talk explores how to navigate this crucial gap. 📌 The Future of Drug Development 🚀 🔹 By integrating Whether you're a researcher, student, or industry professional, this session is packed with insights

. << Back to podcast list Strategic Partner(s) Masha Niv: Bitter Taste Receptors and the Drug Discovery not to be blocked Bitter taste GPCRs are structurally unusual within the broader GPCR family - they lack

. << Back to podcast list Strategic Partner(s) Graciela Pineyro: Resilience, Lab Life, and the Zoom Effect She talks about finally being able to ask which projects deserved to be finished first, second, third We have to go back now and start from scratch." "Zoom democratizes the world. So if we are sent back home, at least we have something to work on." and forth for a while before everything goes back to normal."

And if you stay, your trial fee comes back as a credit. $49 14-days of full Premium access Credited toward Nothing held back. The Math Your trial fee is never lost The $49 comes back as a credit. Either way, you win. Nothing is held back. You get everything Premium members have for 14 days. Can I start anytime? And if you stay, it comes back as a credit toward your first year.

Strategic Partners Back to Partners List Submit Thanks for submitting! We'll get back to you to set up a meeting.

<< Back to podcast list Strategic Partner(s) Dr. Hannes Schihada About Dr. By the end of 2021, I moved back to Germany and joined the pharmaceutical chemistry group of Peter Kolb

. << Back to podcast list Strategic Partner(s) Paul Insel: Unbiased Discovery and the GPCRs We've Been expression, and the low pH of the tumor microenvironment then activates that receptor, which signals back television work, he would probably take a wrecking ball to it and then try to piece all the little parts back molecular pharmacology in cells, and animal models, and as he puts it has now he’s "gone full circle" back